Treatment of acute gynecologic infections with trovafloxacin

Insurance-Related Differences in the Risk of Ruptured Appendix

Paula Braveman, V. Mylo Schaaf, Susan Egerter et al. · New England Journal of Medicine · 1994 · 228 citations · Full text

Public Affairs, Insurance, Health Insurance +14

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

George M. Eliopoulos, K Klimm, C T Eliopoulos et al. · Antimicrobial Agents and Chemotherapy · 1993 · 134 citations

Life Sciences, Microbiology, Antimicrobial Pharmacology +13

In vitro activity of the new fluoroquinolone CP-99,219

Harold C. Neu, N X Chin · Antimicrobial Agents and Chemotherapy · 1994 · 94 citations

Life Sciences, Microbiology, Antimicrobial Pharmacology +9

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

John Vincent, Jürgen Venitz, Rongyue Teng et al. · Journal of Antimicrobial Chemotherapy · 1997 · 65 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria

Hannah M. Wexler, E Molitoris, D. Molitoris et al. · Antimicrobial Agents and Chemotherapy · 1996 · 54 citations · Full text

Life Sciences, Microbiology, Pharmacology +11